Please contact our Professional Congress Organizer MCI for all your WGC-2025 questions wgc@mci-group.com
MCI The Netherlands
Schipluidenlaan 4
1062 HE Amsterdam
The Netherlands
World Glaucoma Association
www.worldglaucoma.org
Thursday, June 29
(7:30 – 8:30 CEST)
| 7.30-7.35 | Welcome and Introductions | Chair: Ike Ahmed (Canada) |
| 7.35-7.50 | Clinically meaningful VF progression and determine Target IOP | Dan Lindfield (United Kingdom) |
| 7.50-8.05 | Will artificial intelligence transform Glaucoma care in future? | Ingeborg Stalmans (Belgium) |
| 8.05-8.20 | Changing dimensions in surgical options: Blebless MIGS vs MIBS | Ike Ahmed (Canada) |
Thursday, June 29
(12:15 – 13:15 CEST)
| 12:15-12:20 | Welcome | Stefano Gandolfi (Italy) |
| 12:20-12:35 | Limitations of drop therapy | Francesco Oddone (Italy) |
| 12:35-12:50 | SLT in RCTs vs. RWE | Anthony Khawaja (United Kingdom) |
| 12:50-13:05 | Targeted Delivery: Role of MMPs in the outflow pathways | Ike Ahmed (Canada) |
| 13:05-13:15 | Q&A and discussion | Stefano Gandolfi (Italy) |
Friday, June 30
(12:15 – 13:15 CEST)
Chairs:
Speakers:
| Time | Title | Presenter |
| 12:15–12:20 | Symposium agenda and objectives | Carlo Traverso (Italy) |
| 12:20–12:33 | Are we ready to change our approach to glaucoma management? | Roberto Carassa (Italy) |
| 12:33–12:46 | A step forward in the interventional glaucoma approach with XEN®63 in patients with primary open-angle-glaucoma | Antonio Fea (Italy) |
| 12:46–12:59 | Maximize the micro-incisional XEN®63 surgery option at the right time: pre-operative preparation, surgery technique and post-operative care | Michele Figus (Italy) |
| 12:59–13:15 | Faculty discussion | Stefano Gandolfi (Italy) Jose M. Martinez de la Casa (Spain) Carlo Traverso (Italy) |
XEN® Gel Implant is a CE Marked class III Medical Device. CE2797
XEN® Gel Implant is intended to reduce intraocular pressure in patients with primary open angle glaucoma where previous medical treatments have failed.
Materials developed in accordance with CE mark.
Registration conditions and licenses differ internationally, please refer to your local Directions for Use. A list of countries with this product/ indication is available from ukmedinfo@abbvie.com For further information please consult your country Directions For Use.
Adverse events should be reported to your Ministry of Health and local AbbVie office.
Medical devices have associated risks, please refer to the contraindications, warnings and precautions sections in the Directions For Use.
Promotional symposium organised and funded by Abbvie.
ALL-XEN-230005 – April 2023
